JP2014517282A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517282A5
JP2014517282A5 JP2014510754A JP2014510754A JP2014517282A5 JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5 JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5
Authority
JP
Japan
Prior art keywords
bladder cancer
subject
prognosis
sample
sample value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517282A (ja
Filing date
Publication date
Priority claimed from EP11166558A external-priority patent/EP2524928A1/en
Application filed filed Critical
Publication of JP2014517282A publication Critical patent/JP2014517282A/ja
Publication of JP2014517282A5 publication Critical patent/JP2014517282A5/ja
Pending legal-status Critical Current

Links

JP2014510754A 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３ Pending JP2014517282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161487341P 2011-05-18 2011-05-18
EP11166558.4 2011-05-18
EP11166558A EP2524928A1 (en) 2011-05-18 2011-05-18 RBM3 in bladder cancer
US61/487,341 2011-05-18
PCT/EP2012/058826 WO2012156330A1 (en) 2011-05-18 2012-05-11 Rbm3 in bladder cancer

Publications (2)

Publication Number Publication Date
JP2014517282A JP2014517282A (ja) 2014-07-17
JP2014517282A5 true JP2014517282A5 (OSRAM) 2015-06-25

Family

ID=44358146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510754A Pending JP2014517282A (ja) 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３

Country Status (6)

Country Link
US (4) US20120040338A1 (OSRAM)
EP (2) EP2524928A1 (OSRAM)
JP (1) JP2014517282A (OSRAM)
AU (1) AU2012257798A1 (OSRAM)
CA (1) CA2834653A1 (OSRAM)
WO (1) WO2012156330A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
EP2746768A1 (en) * 2012-12-20 2014-06-25 Atlas Antibodies AB Podxl in bladder cancer
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN120400338A (zh) 2017-08-07 2025-08-01 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
CN110195109A (zh) * 2019-07-03 2019-09-03 北京太东生物科技有限公司 Rbm46作为睾丸肿瘤标志物的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
US9458495B2 (en) * 2008-07-01 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for assessment of clinical infertility
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis

Similar Documents

Publication Publication Date Title
Yap et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
Hutterer et al. Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma
Todenhöfer et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients
Straver et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy
Shin et al. Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion
Elsawaf et al. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour
Labiche et al. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma
Uhlig et al. Contrast enhancement on cone-beam breast-CT for discrimination of breast cancer immunohistochemical subtypes
Sakamoto et al. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy
Szulkin et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
Kan et al. The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: a retrospective study
Choi et al. Impact of lymph node dissection in radical cystectomy for bladder cancer: how many vs how far?
De-Colle et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity
van der Heijden et al. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy
Pannier et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer
Sun et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy
Park et al. ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma
Ademuyiwa et al. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer
CN117999363A (zh) 用于无细胞的dna表观遗传的胃肠道癌检测以及治疗的组成物和方法
Okamoto et al. Risk factors for complications following lateral pelvic lymph node dissection for rectal cancer
Keruakous et al. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy
Beiki Prognostic value of lymph node ratios in node positive rectal cancer treated with preoperative chemoradiation
JP2016508219A5 (OSRAM)
Harris et al. Quest for the ideal cancer biomarker: an update on progress in capture and characterization of circulating tumor cells
Sharir et al. Lymph node assessment and lymphadenectomy in bladder cancer